Out of REACH

November 20, 2006

Europe's proposed new chemicals legislation, REACH, could disrupt the supply of important medicines. David Vosvenieks, REACH issue manager at AstraZeneca (AZ), told Chemistry & Industry that two companies supplying intermediates required for two AZ drugs - one of them an anticancer therapy- have already warned AZ that they may no longer be able to guarantee supply under the new rules. Pfizer and GlaxoSmithKline have also said they are in discussions with suppliers.

REACH, which could come into force next April, poses a serious threat to supplies of large numbers of intermediates and raw materials used in drug manufacture. 'While the possibility of this happening has always been on our radar, this has come as a rude awakening,' Vosvenieks said.

A change in supplier would mean re-submitting a drug for evaluation by the regulatory authorities. And because a lot of current manufacture is driven by demand, many drug companies would not have stockpiles to cover the re-authorisation period, which according to the UK Medicines and Healthcare products Regulatory Authority could take up to two months. In the worst-case scenario this could mean a delay with restarting supply.

A spokesman for Pfizer, the world's largest pharmaceutical company, admitted the company was also in discussions with suppliers over REACH, but declined to say whether any particular products were affected. GSK is also reviewing suppliers, but a spokesman said that they had not come up against any problems to date.

'Finding a new supplier would be very much a last resort, and would potentially bring extra costs,' Vosvenieks said. Pharmaceutical active ingredients (APIs) are largely exempt from REACH, but many of the solvents and intermediates involved in the manufacture of the final drug formulation will not be. The main chemicals affected will be hazardous chemicals such as carcinogens or mutagens. 'Such compounds may be used in 5 -10% of drug syntheses as a very rough estimate,' according to Vosvenieks.

Many of the smaller or more specialist firms producing them may lack the resources to comply with REACH.
-end-


Society of Chemical Industry

Related Drug Articles from Brightsurf:

New drug that can prevent the drug resistance and adverse effects
A research team in Korea is garnering attention for having developed an anticancer drug that could potentially prevent drug resistance.

Potent drug supply drop, not domestic drug policies, likely behind 2018 OD death downturn
The slight decline in drug overdose deaths in 2018 coincides with Chinese regulations on the powerful opioid carfentanil, rather than the result of domestic U.S. efforts to curb the epidemic, a new analysis reveals.

Old drug standards delay new drug approvals
The more information the FDA has about existing drugs, the longer it takes to OK new ones for the same conditions.

What drug companies spend to bring a new drug to market
Researchers estimated the cost to bring 63 new drugs or biologics to market between 2009 and 2018 using publicly available data on research and development expenditures for these medicines.

New flu drug drives drug resistance in influenza viruses
University of Wisconsin-Madison researchers examined the effects of baloxavir treatment on influenza virus samples collected from patients before and after treatment.

Cause of drug resistance in a drug resistance in intestinal tumors identified
Researchers clarify mechanisms that allow hard-to-treat cancers to develop, and have identified strategies that could lead to new therapies.

AI could offer warnings about serious side effects of drug-drug interactions
Researchers at Penn State have developed a machine learning system that may be able to warn doctors and patients about possible negative side effects that might occur when drugs are mixed.

Charcoal-based drug delivery system improves efficacy of common herpes drug
A study led by researchers from the University of Illinois at Chicago has found that combining acyclovir -- a commonly prescribed topical herpes medication -- with particles of activated carbon improves efficacy of the drug.

Candida auris is a new drug-resistant fungus emerging globally and in the US early detection is key to controlling spread of deadly drug-resistant fungus
Early identification of Candida auris, a potentially deadly fungus that causes bloodstream and intra-abdominal infections, is the key to controlling its spread.

Arming drug hunters, chemists design new reaction for drug discovery
Colorado State University organic chemists have forged a powerful new tool for drug hunters -- a simple, elegantly designed chemical reaction that could fling open an underexplored wing of biologically relevant chemistry.

Read More: Drug News and Drug Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.